Boosting Cancer Chemoimmunotherapy with Mitochondria‐Targeting Iridium(III)‐Based Immunogenic Oncosis Inducers
Angewandte Chemie International Edition · 28.01.2026 · 65 (5)
DOI: 10.1002/anie.202521242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 08.12.2025. Verfasst von Jun Shu und 7 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Basic Re…. Hauptthemen laut MEDLINE: Mitochondria, Iridium, Immunotherapy, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Innovation Program of Hunan Province of China, Chemical Industry Fund of the German Chemical Industry Association.
Abstract (Originalsprache)
Most clinically used chemotherapeutic agents act by inducing apoptosis. However, their clinical effectiveness is often limited by poor therapeutic efficacy and the rapid development of drug resistance. In contrast, oncosis, as an inflammatory form of cell death independent of adenosine triphosphate (ATP) and apoptotic pathways, exhibits unique advantages in overcoming tumor drug resistance and regulating anti‐tumor immune responses. Herein, we present the first iridium(III)‐based immunogenic oncosis inducers designed to concurrently induce oncosis and activate the cGAS–STING pathway, thereby bridging chemotherapy with immunotherapy. Through a bioisosteric design strategy, we identified benzoselenazole and benzothiazole derivatives as key pharmacophores for triggering oncosis. These iridium(III)‐based oncosis‐inducers rapidly disrupt mitochondrial architecture, induce oxidative stress, and promote Ca(II) release, which subsequently activate calpain and porimin to initiate oncosis in multidrug‐resistant cancer cells. Transcriptomic profiling further revealed their ability to regulate actin cytoskeleton organization, modulate ABC transporter activity, and affect glycolysis/gluconeogenesis. Notably, the metal complexes induce mitochondrial swelling and mt‐DNA damage, leading to robust activation of the cGAS–STING innate immune pathway and eliciting a strong anticancer immune response. Based on these multimodal mechanisms, the Ir(III)‐based immunogenic oncosis inducers were able to effectively kill drug‐resistant cancer cells and enhance the anticancer immune response in tumor mouse models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, State Key Laboratory of Anti-Infective Drug Discovery and Development, Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, Scho…
- Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Universitätsstrasse 150, 44780, Bochum, Germany.
- School of Chemistry and Environmental Engineering, Key Laboratory of Green Chemistry of Sichuan Institutes of Higher Education, Sichuan University of Science & Engineering, Zigong, 643000, P.R. China.
- Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, Paris, 75005, France.
- MOE Key Laboratory of Theoretical Organic Chemistry and Functional Molecule, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, 400201, P.R. China.
ORCID-Profile: Hui Chao
Förderung
- National Natural Science Foundation of China
- Science and Technology Innovation Program of Hunan Province of China
- Chemical Industry Fund of the German Chemical Industry Association
- Aventis Foundation
- Paul Ehrlich Foundation
Zitieren
APA
Shu, J., Wu, X., Tang, Z., Feng, T., Karges, J., Jiang, W., Gasser, G., & Chao, H. (2026). Boosting Cancer Chemoimmunotherapy with Mitochondria‐Targeting Iridium(III)‐Based Immunogenic Oncosis Inducers. Angewandte Chemie International Edition, 65(5). https://doi.org/10.1002/anie.202521242
Vancouver
Shu J, Wu X, Tang Z, Feng T, Karges J, Jiang W, et al. Boosting Cancer Chemoimmunotherapy with Mitochondria‐Targeting Iridium(III)‐Based Immunogenic Oncosis Inducers. Angewandte Chemie International Edition. 2026;65(5). doi:10.1002/anie.202521242
BibTeX
@article{Shu2026,
author = {Shu, Jun and Wu, Xianbo and Tang, Zixin and Feng, Tao and Karges, Johannes and Jiang, Weidong and Gasser, Gilles and Chao, Hui},
title = {Boosting Cancer Chemoimmunotherapy with Mitochondria‐Targeting Iridium(III)‐Based Immunogenic Oncosis Inducers},
journal = {Angewandte Chemie International Edition},
year = {2026},
volume = {65},
number = {5},
doi = {10.1002/anie.202521242}
}
EUVIMED